title: Point-of-care platelet function tests: detection of platelet inhibition induced by nonopioid analgesic drugs.
abstract: Detection of platelet inhibition is of clinical relevance in the preinterventional risk-benefit assessment in chronic low-back-pain patients scheduled for invasive pain therapy. We evaluated the sensitivity of various point-of-care platelet function tests for the detection of platelet inhibition induced by nonopioid analgesic drugs. After Institutional Review Board approval and informed consent, citrated whole blood from 40 patients with chronic unspecific low back pain was investigated before and 30 min after intravenous infusion of the study medication consisting of diclofenac 75 mg (plus orphenadrin 30 mg; Neodolpasse; Fresenius Kabi Austria GmbH, Austria), parecoxib 40 mg (Dynastat; Pharmacia Europe EEIG, UK), paracetamol 1 g (Perfalgan; Bieffe Medital S.P.A., Italy), or normal saline in a randomized, cross-over, double-blinded, placebo-controlled study. Platelet function was assessed using the PFA-100 platelet function analyzer and thromboelastometry, as well as impedance aggregometry (in the last 17 patients recruited after it became commercially available). Sensitivity for detecting diclofenac-induced platelet inhibition was 85% for the PFA-100 using epinephrine as agonist and 94% for arachidonic acid-induced impedance aggregometry. ADP-induced platelet function tests, as well as cytochalasin D-modified thromboelastometry were unreliable. All tests had a low incidence of false-positive test results after normal saline. Paracetamol and parecoxib had no significant platelet inhibiting effect. The PFA-100 using epinephrine as agonist and arachidonic acid-induced impedance aggregometry are recommended for the detection of cyclooxygenase-I-inhibiting effects of nonsteroidal anti-inflammatory drugs such as diclofenac. Our findings confirm that a single rescue dose of paracetamol and parecoxib has no antiplatelet effect.
authors.affiliation: Department of Anaesthesiology, General Intensive Care, and Pain Control, Vienna Medical University, Vienna, Austria.
authors.forename: Gisela
authors.initials: G
authors.lastname: Scharbert
authors.forename: Kristina
authors.initials: K
authors.lastname: Gebhardt
authors.forename: Zacharia
authors.initials: Z
authors.lastname: Sow
authors.forename: Monika
authors.initials: M
authors.lastname: Duris
authors.forename: Engelbert
authors.initials: E
authors.lastname: Deusch
authors.forename: Sibylle
authors.initials: S
authors.lastname: Kozek-Langenecker
mesh_terms: D000082:Acetaminophen / Q000009:adverse effects*; D000328:Adult; D000368:Aged; D018712:Analgesics, Non-Narcotic / Q000009:adverse effects; D001792:Blood Platelets / Q000187:drug effects; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects*; D004008:Diclofenac / Q000009:adverse effects; D004311:Double-Blind Method; D005189:False Positive Reactions; D005260:Female; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects*; D017116:Low Back Pain / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects*; D010979:Platelet Function Tests / Q000295:instrumentation* / Q000379:methods; D019095:Point-of-Care Systems; D013916:Thrombelastography / Q000187:drug effects
chemical_list: D018712:Analgesics, Non-Narcotic; D016861:Cyclooxygenase Inhibitors; D007555:Isoxazoles; D004008:Diclofenac; D000082:Acetaminophen; C409945:parecoxib